The release of the highly anticipated Xarelto reversal agent, AndexXa, will be limited to only 40 to 50 hospitals until at least next year, due to concerns the FDA has over the manufacturing process, Portolo Pharmaceuticals CEO told investors.…
A new reversal agent has been approved for Xarelto and Eliquis but will only continue to be approved if postmarketing studies find no problems.…
A jury in Pennsylvania issued a defense verdict in the latest Xarelto bleeding injury lawsuit to go to trial.…
The FDA has granted full approval for the Pradaxa reversal agent, Praxbind, following positive results from phase III clinical trials.…
The FDA is calling for clinical trials before it will approve the long-delayed Xarelto and Eliquis reversal agent, AndexXa.…
A federal judge has ordered case specific discovery for 1,200 Xarelto lawsuits, in what is likely a preparation for the cases to be remanded for individual trial dates.…
A new study finds that aspirin and Xarelto have similar effectiveness at preventing blood clots and similar bleeding risks following hip and knee replacement surgery.…
A new study warns that older patients with chronic kidney disease may face an increased risk of stroke due to the side effects of Xarelto, Warfarin, Heparin and other blood thinners meant to decrease their risk of stroke due to atrial fibrillation.…
A new study finds that the side effects of blood thinners like Xarelto and Pradaxa may increase the risk of bleeding in patients with acute coronary syndromes when used with antiplatelet therapy.…
New blood thinners and warfarin both increase the risk of death among hospital patients with intracranial bleeding, indicate the findings of a new study.…
